Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 7 , ISSUE 1 ( January-June, 2017 ) > List of Articles

BRIEF REPORT

Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh

Mohammad H Uddin, Sheikh MN Alam, Ahmed L Moben, Mohammad A Alam

Citation Information : Uddin MH, Alam SM, Moben AL, Alam MA. Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh. Euroasian J Hepatogastroenterol 2017; 7 (1):113-115.

DOI: 10.5005/jp-journals-10018-1229

License: CC BY 3.0

Published Online: 00-06-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction

Decompensated cirrhosis is associated with significantly high mortality resulting from hepatic failure, and liver transplantation seems to be the only viable indication for its management. The objective of this study is to assess if granulocyte colony-stimulating factor (G-CSF), a stimulatory of stem cell in vivo, may be of any benefit for patients with decompensated cirrhosis of liver.

Materials and methods

Seventeen consecutive patients with decompensated cirrhosis of liver were recruited in this prospective study. They received injection of G-CSF (30 IU) over a period of 6 weeks (12 injections) in addition to standard of care.

Results

Patients were followed up at the end of treatment and at 12 weeks of treatment. Treatment was well tolerated, and no significant adverse event was recorded in any patient. Fifteen out of 17 (88%) patients were alive at last follow-up. Although serum bilirubin, albumin, and prothrombin time improved in some patients, statistically significant improvement of Child–Pugh score could not be documented.

Conclusion

The study establishes the safety of G-CSF therapy in patients with decompensated cirrhosis of liver. Besides, such therapy may also have survival benefit, although long-term follow-up is needed to assess its real utility in clinical perspectives.

How to cite this article

Al Mahtab M, Alam SMN, Moben AL, Raihan R, Alam MA, Rahim MA, Uddin MH, Akbar SMF. Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh. Euroasian J Hepato-Gastroenterol 2017;7(1):113-115.

Source of support

The study was partially supported by a grant from Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh


  1. Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. Hepatol Int 2013 Oct;7(4):1075-1083.
  2. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015 Jun;148(7):1362.e7-1370.e7.
  3. Clinical profile and predictor of mortality in patient of acute on chronic liver failure (ACLF). Dig Liver Dis 2012 Feb;44(2):166-171.
  4. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013 Feb;19(7):1104-1110.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.